³í´Ü

±èÁ¤¿¬
³ú¿¡¼­ ÀÎÁöÁú ºÐÇØÈ¿¼ÒC ¿Í Á¤¼­ÀÎÁöÀå¾Ö
±èÁ¤¿¬ Çѱ¹³ú¿¬±¸¿ø
¸ÞÀÏ jykim@kbri.re.kr

[¼­·Ð]

   ¿ì¸®ÀÇ ÇൿÀ» À¯¹ßÇÏ´Â °ÍÀº ÀÏÂ÷ÀûÀ¸·Î ±Ù¿øÀûÀÎ °¨Á¤°ú ¿å±¸ÀÔ´Ï´Ù. ¹è°¡ °íÇÁ¸é À½½ÄÀ» ã°í, ¾îµÎ¿òÀÌ ¹«¼­¿ì¸é ºûÀ» ã½À´Ï´Ù. ÀÌ·¸µí ´Ù¾çÇÑ °¨°¢Á¤º¸¸¦ ¼ö¿ëÇÏ°í ÃÖÁ¾ÀûÀ¸·Î ÀûÀýÇÑ ÇൿÀ» ÃëÇϵµ·Ï ÇÏ´Â ÁßÃßÀûÀÎ ¿ªÈ°À» ´ã´çÇÏ´Â ½Åü±â°üÀº ³úÀÔ´Ï´Ù. ¹è°íÇÄÀ» ÀνÄÇÏ´Â ³ú¿µ¿ªÀ¸·Î ½Ã»óÀÇ ³ú½ÇÃøÇÙÀÌ ¾Ë·ÁÁ® ÀÖÀ¸¸ç, °øÆ÷°¨À» Çü¼ºÇÏ°í Á¶ÀýÇÏ´Â ÁÖ¿ä ³ú¿µ¿ªÀº ÆíµµÃ¼ÀÔ´Ï´Ù. ½Ã»ó, ÆíµµÃ¼¸¦ Æ÷ÇÔÇÏ´Â º¯¿¬°è ½Ã½ºÅÛÀº ÁÖ·Î Èñ·Î¾Ö¶ô°ú °°Àº Á¤¼­¸¦ Á¶ÀýÇϸç, ÇнÀÀ» °­È­ÇÏ°í, µ¿±â À¯¹ß¿¡ ±â¿©ÇÕ´Ï´Ù. ¹«±â·ÂÇÔ, ±Ø½ÉÇÑ ºÒ¾È, ÃÊÁ¶, »çȸ¼º °áÇ̵î ÀÏ»ó»ýÈ°¿¡ ¾î·Á¿òÀ» ÃÊ·¡ÇÏ°Ô µÇ´Â ¿ì¿ïÁõ, ºÒ¾ÈÀå¾Ö, ÀÚÆóÁõ µîÀÇ ÁúȯÀº Á¤¼­¡¤ÀÎÁö±â´ÉÀ» ´ã´çÇÏ´Â ³ú¿µ¿ª, ¶Ç´Â ³ú¿µ¿ª°£ ¿¬°á¼ºÀÇ ¼Õ»óÀ¸·Î ¹ßº´ÇÏ´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù.

³ú´Â º¹ÀâÇÑ »ý¹°ÇÐÀû ½Ã½ºÅÛÀ¸·Î ÈïºÐ¼º ½Å°æ¼¼Æ÷, ¾ïÁ¦¼º ½Å°æ¼¼Æ÷, ¼º»ó±³¼¼Æ÷, ¹Ì¼¼ ¾Æ±³¼¼Æ÷µî ´Ù¾çÇÑ ¼¼Æ÷ŸÀÔÀ¸·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç, °°Àº ³ú¿µ¿ª¿¡ ¸ðÀÎ ½Å°æ¼¼Æ÷°£¿¡µµ ¼±ÅÃÀûÀ¸·Î ¹ßÇöÇÏ´Â ºÐÀÚ¸¶Ä¿¿¡ µû¶ó ƯÁ¤ ½Å°æ¼¼Æ÷ŸÀÔÀ¸·Î ±¸º°µË´Ï´Ù. 1000¾ï°³°¡ ³Ñ´Â ½Å°æ¼¼Æ÷´Â ½Ã³À½º¶ó´Â ±¸Á¶¸¦ ÅëÇØ ¿¬°áµÇ¾î ½Å°æȸ·Î¸¦ Çü¼ºÇÏ°í, Àü±âÀû, È­ÇÐÀû ¹ÝÀÀÀÇ »óÈ£ÀÛ¿ëÀ» ÅëÇØ ´Ù¸¥ ½Å°æ¼¼Æ÷¿¡ Á¤º¸¸¦ Àü´ÞÇÏ¿© ƯÁ¤ Çൿ¾ç½ÄÀ» Á¶ÀýÇÏ°Ô µË´Ï´Ù. ½Å°æ¼¼Æ÷°£ÀÇ ¼ÒÅëÀº Àü ½Ã³À½º¿¡¼­ ºÐºñµÇ´Â ½Å°æÀü´Þ¹°ÁúÀÌ ÈÄ ½Ã³À½ºÀÇ ½Å°æÀü´Þ¹°Áú ¼ö¿ëü¿Í °áÇÕÇÏ¿© Á¤º¸°¡ Àü´ÞµÇ¸ç, ¼ö¿ëü´Â ½Å°æ¼¼Æ÷³» ½ÅÈ£Àü´Þü°è¸¦ È°¼ºÈ­½Ãŵ´Ï´Ù. ÃÖ±Ù ½Å°æ¼¼Æ÷¸¸ÀÌ ¾Æ´Ï¶ó, ¼º»ó±³¼¼Æ÷¿¡¼­µµ ½Å°æÀü´Þ¹°ÁúÀÌ ºÐºñµÇ¾î ½Å°æȸ·Î¿¡ ±â¿©Çϸç [1,2], ¼º»ó±³¼¼Æ÷ ¹× ¹Ì¼¼¾Æ±³¼¼Æ÷ÀÇ °æ¿ì ½Ã³À½º Á¦°Å¿¡ °ü¿©ÇÏ´Â ±âÀÛ [3]À» ÅëÇØ ½Å°æ¼¼Æ÷ÀÇ Á¤º¸ 󸮰úÁ¤¿¡ Å©°Ô °ü¿©ÇÏ´Â °ÍÀÌ ¹àÇôÁ³½À´Ï´Ù [4].

ÀÎÁöÁú ºÐÇØÈ¿¼Ò C (PLC, phospholipase C)´Â ¼¼Æ÷¸·¿¡ Á¸ÀçÇϴ Ƽ·Î½Å Ä«À̳×ÀÌÁî ¼ö¿ëü (Trk, tyrosin kianse receptor) ¶Ç´Â G´Ü¹éÁú °áÇÕ ¼ö¿ëü (GPCR, G-protein coupled receptor)°¡ °¢ ³úÀ¯·¡ ½Å°æ ¼ºÀå ÀÎÀÚ (BDNF, brain-derived neurotrophic factor) ¶Ç´Â ±Û·çŸ¸ÞÀÌÆ® (glutamate) ÀÇÇØ È°¼ºÈ­µÇ¾î phosphatidylinositol 4,5-bisphosphate (PIP2)¸¦ inositol 1,4,5-trisphosphate (IP3)¿Í diacylglycerol (DAG) °¡¼öºÐÇØÇÏ´Â ÀÛ¿ëÀ» ÇÕ´Ï´Ù. ÀÌÈÄ ÀÌÂ÷ ¸Þ½ÅÀúÀÎ IP3´Â ¼ÒÆ÷üÀÇ IP3 ¼ö¿ëü¸¦ È°¼ºÈ­½ÃÄÑ ¼¼Æ÷Áú¿¡ Ä®½·À» ¹æÃâ½ÃÅ°°í, ´Ù¸¥ ÀÌÂ÷ ¸Þ½ÅÀúÀÎ DAG´Â PKC¿Í °°Àº Ä«À̳×ÀÌÁ È°¼ºÈ­½ÃÄÑ ½Å°æ¼¼Æ÷ÀÇ È°¼ºÀ» À¯µµÇÏ°í, ½Ã³À½º °­È­, ½Ã³À½º À̿ ä³Î ÀλêÈ­¿Í °°Àº ½Å°æȸ·Î º¯È­¸¦ À¯µµÇÕ´Ï´Ù[5,6,7]. ÀÌ·¸µí ÁÖ¿äÇÑ ¼¼Æ÷ ¹ÛÀÇ º¯È­¿Í ¼¼Æ÷ ³» º¯È­¸¦ Áß°³ÇÏ´Â PLC´Â ¼¼Æ÷³» Ä®½· ³óµµ Á¶Àý°ú ¼¼Æ÷³» ½ÅÈ£Àü´Þ°æ·Î¿¡¼­ÀÇ ±³Â÷Á¡°ú °°´Ù°í ÇÏ°Ú½À´Ï´Ù.

ÀÌ ±Û¿¡¼­´Â ³ú¿¡¼­ PLCÀÇ ´Ù¾çÇÑ µ¿À§Ã¼(isoform)¿Í À̵éÀÇ ºÐÆ÷. ¶ÇÇÑ ´Ù¾çÇÑ PLC°¡ ½Ã³À½º ¹× ½Å°æ °¡¼Ò¼º¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ¼Ò°³ÇÒ±î ÇÕ´Ï´Ù. ¶ÇÇÑ °ü·ÃµÈ Á¤¼­ÀÎÁöÀå¾Ö¸¦ ¼Ò°³ÇÔÀ¸·Î½á À̸¦ Ä¡·áÇÒ ¼ö Àִ ǥÀûÀ¸·Î¼­ PLCÀÇ ÀáÀç·ÂÀ» Á¶¸íÇÏ°íÀÚ ÇÕ´Ï´Ù.

±×¸² 1. 1Â÷ ¹× 2Â÷ PLCÀÇ ½ÅÈ£ °æ·Î¿¡¼­ ÀÛ¿ë±âÀü
±×¸² 1. 1Â÷ ¹× 2Â÷ PLCÀÇ ½ÅÈ£ °æ·Î¿¡¼­ ÀÛ¿ë±âÀü
1Â÷ PLC´Â ¼¼Æ÷¸·ÀÇ G°áÇÕ ´Ü¹éÁú ¼ö¿ëü, ȤÀº ¼ö¿ëü Ƽ·Î½Å Ä«À̳×ÀÌÁî¿¡ ÀÇÇØ È°¼ºÈ­µÇ¸ç, 2Â÷ PLC´Â Ä®½· À̿¿¡ ´õ ¹Î°¨ÇÏ°Ô ¹ÝÀÀÇÏ¿© »óÀ§ Ä®½· ¹ÝÀÀÀ» È®»ê½ÃÅ°´Â ¿ªÇÒÀ» ¼öÇàÇÑ´Ù.

[º»·Ð]

1. PLCÀÇ ´Ù¾çÇÑ µ¿À§Ã¼.

   PLC´Â ´Ù¾çÇÑ µ¿À§Ã¼¸¦ °¡Áö°í ÀÖÀ¸¸ç, ÇöÀç±îÁö PLC¥â1-4, PLC¥ã1,2, PLC¥ä1,3,4, PLC¥å, PLC¥æ, PLC¥ç1, 2 °¡ ¹ß°ßµÇ¾ú½À´Ï´Ù. ÀÌ µ¿À§Ã¼µéÀº Å©°Ô 1Â÷ ¹× 2Â÷ PLC·Î ºÐ·ùµÇ¸ç, 1Â÷ PLC´Â ¼ö¿ëü·ÎºÎÅÍ Á÷Á¢ÀûÀ¸·Î È°¼ºÈ­µÇ´Â ´Ü¹éÁú·Î, PLC¥â, PLC°¡ ÀÌ¿¡ ¼ÓÇÕ´Ï´Ù. PLC¥â´Â ¹«½ºÄ«¸°¼º ¾Æ¼¼Æ¿Äݸ° ¼ö¿ëü(mAChRs)¿Í °°Àº G´Ü¹éÁú °áÇÕ ¼ö¿ëü(GPCR)¿¡ ÀÇÇØ Æ¯ÀÌÀûÀ¸·Î È°¼ºÈ­µÇ¸ç, PLC¥ã´Â ³ú À¯·¡ ½Å°æ¼ºÀå ÀÎÀÚ (BDNF) ¼ö¿ëü¿Í °°Àº ¼ö¿ëü Ƽ·Î½Å Ä«À̳×ÀÌÁî(RTK, receptor tyrosine kinase)¿¡ ÀÇÇØ È°¼ºÈ­µË´Ï´Ù. ÇÑÆí PLC¥å, PLC¥ç°¡ Æ÷ÇÔµÈ 2Â÷ PLC´Â 1Â÷ PLC¿Í ´Þ¸® ¼ö¿ëü·ÎºÎÅÍ Á÷Á¢ È°¼ºÈ­µÇÁö ¾ÊÀ¸¸ç, 1Â÷ PLCÀÇ ÀÛ¿ë¿¡ ÀÇÇØ ³ô¾ÆÁø ¼¼Æ÷Áú Ä®½· ³óµµ¸¦ °¨ÁöÇÏ¿© È°¼ºÈ­µÇ´Âµ¥, 2Â÷ PLC´Â 1Â÷ PLC·ÎºÎÅÍ ½ÃÀÛµÈ Ä®½· ½ÅÈ£Àü´Þ °æ·Î¿¡ ¾ç¼º Çǵå¹éÀ» ÀÏÀ¸ÄÑ ½ÅÈ£¸¦ ÁõÆø½ÃŲ´Ù´Â Á¡ÀÌ 1Â÷ PLC¿Í ±¸º°µÇ´Â ±â´ÉÀÔ´Ï´Ù [5,7,8].

³ú¿¡¼­ PLC µ¿À§Ã¼µéÀÇ ´Ù¾çÇÑ ³ú ¿µ¿ª¿¡¼­ »óÀÌÇÑ ¹ßÇö¾ç»óÀ» º¸ÀÔ´Ï´Ù. °°Àº µ¿À§Ã¼°¡ ´ëºÎºÐÀÇ ³ú ¿µ¿ª¿¡ °ÉÃÄ ºÐÆ÷Çϱ⵵ Çϸç, ¼±ÅÃÀûÀÎ ³ú¿µ¿ª¿¡¼­¸¸ ¹ßÇöÇϱ⵵ ÇÕ´Ï´Ù. ¶Ç´ÂPLC¥â1 ¿Í PLC¥ã1°¡ Çظ¶¿¡¼­ ÇÔ²² ¹ßÇöµÇ´Â °Íó·³ ¿©·¯ µ¿À§Ã¼°¡ µ¿½Ã¿¡ °°Àº ³ú¿µ¿ª¿¡¼­ ³ªÅ¸³ª±âµµ ÇÕ´Ï´Ù.

³ú¿¡¼­ °¡Àå µÎµå·¯Áö°Ô ¹ßÇöÇÏ´Â PLC µ¿À§Ã¼´Â PLC¥â1-4, PLC¥ã1, PLC¥å ±×¸®°í PLC¥çÀÔ´Ï´Ù. ÀÌÁß °¡Àå ¸¹ÀÌ ¹ßÇöÇÏ´Â µ¿À§Ã¼ ±×·ìÀº PLC¥â1·Î¼­, Çظ¶¿Í ´ë³ú ÇÇÁú¿¡¼­ À¯ÀǹÌÇÏ°Ô ¹ßÇöµÇ¸ç, ƯÈ÷ ¼Ò³úÀÇ ´Ù¾çÇÑ ½Å°æ¼¼Æ÷(cerebellar interneurons, telencephalic principal neurons)¿¡¼­ ¿ì¼¼ÇÏ°Ô ¹ßÇöµË´Ï´Ù. PLC¥â2´Â ¹Ì·Ú¿Í ¹Ì°¢ ±â°ü ¹ß´ÞÀÇ ºÐÈ­ ¸¶Ä¿·Î »ç¿ëµË´Ï´Ù PLC¥â3´Â Àΰ£ ¿øÃßÇü ±¤¼ö¿ëü ½Å°æ¼¼Æ÷¿¡¼­ ³ªÅ¸³ª¸ç, PLC¥â4´Â ¹è¾Æ ÈıâºÎÅÍ ¼Ò³ú, ¸Á¸·, ¼Ò³ú Ǫ¸£Å²¿¹ ¼¼Æ÷ (purkinje cell)¿¡¼­ ÁÖ·Î ¹ßÇöµË´Ï´Ù [5,7]. PLC¥ã1Àº Çظ¶, ÆíµµÃ¼, Àü³ú¿¡¼­ µÎµå·¯Áö°Ô ¹ßÇöµÇ¸ç ƯÈ÷ žÆÀÇ ³ú ¹ß´Þ Áß ¹æ»ç»ó ½Å°æ±³¼¼Æ÷¿¡ dzºÎÇÏ°Ô ¹ßÇöµË´Ï´Ù. PLC¥ã2´Â ³úÇϼöü Àü¿±°ú ¼Ò³ú Ǫ¸£Å²¿¹ ¹× °ú¸³ ¼¼Æ÷ÀÇ Á¦ÇÑµÈ ¿µ¿ª¿¡¼­ ³ªÅ¸³ª¸ç, ¹Ì¼¼¾Æ±³¼¼Æ÷¿¡¼­ ÁÖ·Î ¹ßÇöÇÏ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. PLC¥å´Â ½Å°æ¼¼Æ÷ °èÅë ºÐÈ­¿Í °ü·ÃÀÌ ÀÖÀ¸¸ç ¹è¾Æ ´Ü°èÀÇ ½Å°æ°ü °¡Àå ¹Ù±ùÃþ°ú ³ú, ô¼ö, ÈÄ°¢ »óÇÇ, ¸Á¸·ÀÇ °¡ÀåÀÚ¸® ¿µ¿ª¿¡ ÁַΠdzºÎÇÕ´Ï´Ù. PLC¥ä4´Â ³ú¿Í Àç»ý Á¶Á÷¿¡¼­ ¹ßÇöÀÌ ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. °¡Àå ÃÖ±Ù¿¡ ¹ß°ßµÈPLC¥ç´Â »ó´ëÀûÀ¸·Î ³ú¿¡¼­ °­ÇÑ ¹ßÇöÀ» º¸À̸ç, PLC¥ç2ÀÇ °æ¿ì ½Å°æ¼¼Æ÷ ¼±ÅÃÀûÀ¸·Î ¹ßÇöÇÏ°í ÀÖ½À´Ï´Ù [7,9,10,11].

ÀÌ·¸µí ´Ù¸éÀûÀ¸·Î ³ªÅ¸³ª´Â PLC µ¿À§Ã¼ÀÇ ¹ßÇö ÆÐÅÏ¿¡ ´ëÇÑ ÀÌÇØ ¹× º¹ÀâÇÑ »óÈ£ ÀÛ¿ë, È°¼ºÈ­ ¸ÞÄ¿´ÏÁò, ³ú »ý¸®Çп¡¼­ÀÇ ¿ªÇÒÀ» ÀÌÇØÇÏ´Â °ÍÀº ³ú ±â´ÉÀÇ º¹À⼺À» Ç®±â À§ÇÑ Áß¿äÇÑ ½Ç¸¶¸®¸¦ Ç°°í ÀÖÀ» °ÍÀÔ´Ï´Ù. ¸¸¼º °£ ¿°Áõ Áúȯ°ú NLRP3 ÀÎÇöó¸¶Á»Àº ¹ÐÁ¢ÇÑ »ó°ü°ü°è°¡ ÀÖ½À´Ï´Ù. Áö¹æ°£¿° ¹× °£°æº¯ ȯÀÚ¿¡°Ô¼­ ´ëüÀûÀ¸·Î °£ ³» NLRP3, IL-1¥â, IL-18, ¹× caspase-1ÀÇ ¹ßÇö ¹× È°¼ºÀÌ Áõ°¡µÇ¾î ÀÖ½À´Ï´Ù [12,13]. °£ÀÇ ÀÎÇöó¸¶Á» È°¼ºÈ­´Â °£ ³» ¸é¿ª¼¼Æ÷ÀÇ À¯ÀÔ, ¿°Áõ À¯µµ, °£ ¼¶À¯È­ÁõÀ» À¯¹ß½ÃÅ°´Â ÁÖ¿ä °£ Áúȯ ÀÎÀÚÀÔ´Ï´Ù. ½ÇÁ¦, NLRP3, ASC, ¹× caspase-1ÀÇ ÀÎÇöó¸¶Á» º¹ÇÕü°¡ °áÇÌÀÌ µÇ¸é °£¼¼Æ÷ »ç¸ê, ¿°Áõ ¹× °£ ¼¶À¯È­ÁõÀÌ ¿ÏÈ­µÇ´Â °ÍÀ» ÅëÇØ ÀÎÇöó¸¶Á»ÀÌ °£ Áúȯ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ½ÇÇèÀûÀ¸·Î È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù [14,15,16]. ´ëÇ¥ÀûÀÎ NLRP3 inhibitor Áß ÇϳªÀÎ ÀúºÐÀÚÈ­ÇÕ¹° MCC950À» ¾Æ¹Ì³ë»ê °áÇÌ (methionine-choline deficient; MCD) ½ÄÀÌ¿ä¹ý À¯µµ NASH ¸¶¿ì½º ¸ðµ¨¿¡ ó¸®ÇÏ¸é °£ÀÇ ¿°Áõ, Áö¹æ ÃàÀû, ¼¶À¯È­ÁõÀÌ ¿ÏÈ­µÉ ¼ö ÀÖ½À´Ï´Ù [17]. ÀÌ´Â, °£ ³» NLRP3 ÀÎÇöó¸¶Á» ¸Å°³ IL-1¥â ¹× IL-18 »çÀÌÅäÄ«ÀÎÀÌ °£ ÁúȯÀÇ ÁøÇà¿¡ ÀÖ¾î Áß¿äÇÑ ¿ªÇÒÀ» ÇÔÀ» ½Ã»çÇÕ´Ï´Ù.

2. ³ú¹ß´Þ ¹× ³ú±â´É°ú °ü·ÃµÈ º¸°í

   PLC¥â µ¿À§Ã¼, ƯÈ÷ PLC¥â1Àº ³úÀÇ ¹ß´Þ°ú ±â´É¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇÕ´Ï´Ù. PLC¥â1Àº Á¤»óÀûÀÎ ´ë³ú ÇÇÁú ȸ·ÎÀÇ È°µ¿ ÀÇÁ¸Àû ¹ß´Þ ¹× ´ë³ú ÇÇÁúÀÇ ½Å°æ°¡¼Ò¼º¿¡ °ü¿©ÇÕ´Ï´Ù. PLC¥â1Àº ´ë»ç¼º ±Û·çŸ¸ÞÀÌÆ® ¼ö¿ëü(mGluR, metabotropic glutamate receptor) ¹× ¹«½ºÄ«¸°-Äݸ°¼º ¼ö¿ëü(mAChR, muscarinic acetylcholine receptor)¿Í °°Àº ƯÁ¤ ¼ö¿ëüÀÇ È°¼ºÈ­¸¦ ÅëÇØ Ä®½· ½ÅÈ£¸¦ Á¶ÀýÇÕ´Ï´Ù. À̸¦ ÅëÇØ PLC¥â1Àº ¶ÇÇÑ ¼¼Æ÷ ÁÖ±â ÁøÇà ¹× ¼¼Æ÷ Áõ½Ä Á¶Àý¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸·Î »ý°¢µË´Ï´Ù. ÇÑÆí ¼º»ó±³¼¼Æ÷ µµÆĹο¡ ÀÇÇÑ ¼¼Æ÷³» Ä®½· Áõ°¡°¡ °üÂûµÇ´Âµ¥, ÀÌ ¶ÇÇÑ G´Ü¹éÁú °áÇÕ ¼ö¿ëüÀÎ µµÆĹΠ¼ö¿ëü¿Í »óÈ£ÀÛ¿ëÇÏ´Â PLC¥â µ¿À§Ã¼¿Í ¿¬°üÀÌ ÀÖÀ» °ÍÀ¸·Î ¿©°ÜÁý´Ï´Ù [8,18].

PLC¥ã µ¿À§Ã¼ÀÇ °æ¿ì¿¡´Â, PLC¥ã1°¡ ³ú¿¡ ÁÖ¿äÇÏ°Ô ¹ßÇöÇÏ°í ÀÖÀ¸¸ç, BDNF-TrkBÇÏÀ§ ½ÅÈ£Àü´Þ°æ·Î Áß¿ä ºÐÀÚ¹°Áú·Î, PLC¥ã´Â ½Å°æ ¼¼Æ÷ ºÎÂø ºÐÀÚ(NCAM, neural cell adhesion molecule)¿ÍÀÇ Çù·ÂÀ» ÅëÇØ ½Å°æ ¼¼Æ÷ ºÐÈ­¸¦ ÃËÁøÇÏ¿© Çظ¶ ½Å°æ¼¼Æ÷ÀÇ Ä®½· ¼öÁØÀ» Áõ°¡½Ãŵ´Ï´Ù. PLC¥ã1Àº ½Å°æ ¼¼Æ÷ À̵¿, ½Å°æ ¼¼Æ÷ ¼º¼÷ Áß Ä®½·ÀÌ¿ÂÀÇ ÀÚ¹ßÀû Áøµ¿ÀÇ ½ÃÀÛ, ½Ã³À½º Àü/ÈÄ ¼öÁØ¿¡¼­ÀÇ ½Å°æ Àü´Þ Á¶Àý¿¡ °ü¿©ÇÏ¿©, ±Û·çŸ¸ÞÀÌÆ®, °¡¹Ù(GABA, ¥ã-aminobutyric acid) °°Àº ½Å°æÀü´Þ¹°ÁúÀÇ ¹æÃâÀ» Á¶ÀýÇÏ°í ½Å°æ ¹ß´Þ°ú °¡¼Ò¼º¿¡ °ü¿©ÇÕ´Ï´Ù. ƯÈ÷ ÇнÀ°ú ±â¾ïÀ» ÀúÀåÇÏ´Â ½Ã³À½º ±âÀüÀ¸·Î ¾Ë·ÁÁø Àå±â ½Ã³À½º °­È­ (LTP, long-term potentiation)¿¡ PLC¥ã1ÀÌ ¸Å°³ÇÏ´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù [6,8,19]. ÇÑÆí ¹Ì¼¼¾Æ±³¼¼Æ÷¿¡ ¼±ÅÃÀûÀ¸·Î ¹ßÇöÇÏ´Â PLC¥ã2´Â ¸é¿ª°ü¹®ºÐÀÚÀÎ TREM2(Triggering Receptor Expressed on Myeloid Cells 2)¿¡ ÀÇÇØ È°¼ºÈ­µÇ¸ç, ³ú³» ºÒÇÊ¿äÇÑ ¹°ÁúµéÀ» û¼ÒÇÏ´Â ÀÛ¿ëÀ» Á¶ÀýÇÏ°í ÀÖ½À´Ï´Ù [20].

´Ù¸¥ µ¿À§Ã¼µéÀº PLC¥â ¶Ç´Â PLC¥ã µ¿À§Ã¼¿¡ ºñÇؼ­´Â ¸¹ÀÌ ¿¬±¸µÇÁö ¾Ê¾ÒÀ¸³ª, PLC¥ä´Â ½Å°æ¼¼Æ÷ÀÇ ¼¼Æ÷¸· ¼¼·ÎÅä´Ñ ¼ö¿ëü·ÎºÎÅÍ ½ÃÀ۵Ǵ ½Å°æ°æ·Î¿¡ Âü¿©ÇÔÀ¸·Î½á µÎ°³¾È¸é ¹× ½ÉÇ÷°ü ÇüÅ Çü¼º¿¡ °ü¿©ÇÕ´Ï´Ù. PLC¥ä´Â M-ŸÀÔ Ä®·ý ä³ÎÀÇ °³Æó »óŸ¦ Á¶ÀýÇÏ°í »êÈ­Áú¼Ò(NO) ¸Å°³ È°¼ºÈ­¸¦ ÅëÇØ N-¸ÞÆ¿-D-¾Æ½ºÆĸ£Æ®»ê¿°(NMDA, N-methyl-D-aspartate)¿¡ ÀÇÇÑ ½Ã³À½º ÈïºÐ°ú ½Å°æ ¹ß»ý¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀ¸·Î »ý°¢µË´Ï´Ù. [6,8] ÇÑÆí PLC¥çÀÇ µ¹¿¬º¯ÀÌ´Â Àΰ£ Å¾ƹߴ޿¡¼­ ÀüÀü³úÁõ (holoprosencephaly) º¸°í°¡ ÀÖÀ¸¸ç, ÀÚÆóÁõ ȯÀÚ ³ú¿¡¼­ À¯ÀüÀû º¯ÀÌ°¡ ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù [12,10].

³úÀüÁõ ³úº´Áõ. [13]
Á¶Çöº´[14,15]
¿ì¿ïÁõ[16,17]

¿îµ¿½ÇÁ¶Áõ ¹× ½Ã°¢ ÀÌ»ó. [21]
½Ã»ó¿¡¼­ ¼ö¸é Á¶Àý. [22]

¾ç±Ø¼º Àå¾Ö[23]
³úÀüÁõ[24]
ÇåÆÃÅÏ º´[25]
¿ì¿ïÁõ[26]

¾ËÃ÷ÇÏÀ̸Ӻ´[27]
½Å°æ ¿°Áõ¿¡ °ü¿©[28]
°á¼Õ½Ã ÅÂ¾Æ ÀüÀü³úÁõ À¯¹ß[12], ÀÚÆóÁõ[10]

Ç¥ 1. ³ú ¹ßÇöÀÌ È®ÀÎµÈ ÁÖ¿ä PLC µ¿À§Ã¼ÀÇ ±â´É°ú °ü·ÃµÈ ÁÖ¿ä Á¤¼­ÀÎÁöÀå¾Ö ¹× ½Å°æÀå¾Ö
Ç¥ 1. ³ú ¹ßÇöÀÌ È®ÀÎµÈ ÁÖ¿ä PLC µ¿À§Ã¼ÀÇ ±â´É°ú °ü·ÃµÈ ÁÖ¿ä Á¤¼­ÀÎÁöÀå¾Ö ¹× ½Å°æÀå¾Ö

3. Á¤¼­ÀÎÁöÁúȯ¿¡¼­ PLC

   ÃÖ±Ù ¿¬±¸¿¡¼­ PLC´Â ´ë³ú ÇÇÁú, Çظ¶, ÆíµµÃ¼, ¼Ò³úµîÀÇ ´Ù¾çÇÑ ³ú¿µ¿ª¿¡¼­ °­ÇÑ ¹ßÇöÀÌ È®ÀεǾúÀ¸¸ç, ³ú Áúȯ¿¡¼­ ÁÖ¿ä µ¿À§Ã¼ÀÎ PLC¥â1¿Í PLC¥ã1¿ÍÀÇ »ó°ü¼ºÀÌ ¹àÇôÁ³½À´Ï´Ù.

³úÀüÁõ¿¡¼­PLC¥â1°ú PLC¥ã1ÀÇ µÎ °¡Áö PLC µ¿À§Ã¼°¡ °ü¿©ÇÏ´Â °ÍÀÌ º¸°íµÇ¾ú½À´Ï´Ù. PLC¥â1 °áÇÌ ¸¶¿ì½º´Â ½É°¢ÇÑ °­Á÷¼º ¹ßÀÛÀ» º¸¿´À¸¸ç [29], ¾ïÁ¦¼º ½Å°æ¼¼Æ÷¿¡¼­ PLC¥ã1°áÇÌ ¸¶¿ì½º¿¡¼­µµ ½Å°æ¼¼Æ÷ÀÇ ºñÁ¤»óÀûÀÎ °úÈ°¼ºÀÌ ¾ß±âµÇ¾î, ³úÀüÁõÀ» À¯¹ßÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ³½À´Ï´Ù [24]. Àΰ£¿¡¼­ PLC¥â1 À¯ÀüÀÚÀÇ µ¿Çü Á¢ÇÕ °á½ÇÀº À¯¾Æ±â ½Ã±âÀÇ ¹ßÀÛ°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù [13].

¾ËÃ÷ÇÏÀ̸Ӻ´ ¹× ÇåÆÃÅϺ´°ú °°Àº ½Å°æ ÅðÇ༺ Àå¾Ö µ¿¹°¸ðµ¨¿¡¼­ ¹ß°ßµÇ´Â BDNF-TrkB ½ÅÈ£Àü´Þ°æ·ÎÀÇ ¼Õ»óÀº, À̸¦ ¸Å°³ÇÏ´Â PLC¥ã1¿ÍÀÇ °­ÇÑ ¿¬°üÀ» ½Ã»çÇÕ´Ï´Ù. ƯÈ÷ ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ ÁÖ¿äÇÑ º´¸®Àû °æ·ÎÀÎ ¾Æ¹Ð·ÎÀ̵å ÇöóÅ©·ÎºÎÅÍ ½Å°æÀ» º¸È£ÇÏ´Â ¿ªÇÒÀ» ÇÏ´Â ¾ÆÆ÷ÁöÁú´Ü¹éÁú (LpE, Apolipoprotein E-containing lipoprotein)ÀÇ ±â´É ¼Õ»óÀÌ ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ ÁøÇà¿¡ °ü¿©ÇÒ °ÍÀ̶ó´Â °¡´É¼ºÀÌ ´ëµÎµÇ¾ú´Âµ¥, LpEÀÇ ½Å°æº¸È£±âÀü¿¡ PLC¥ã1°¡ °ü·ÃµÇ¾î ÀÖ´Ù´Â °ÍÀÌ ¾Ë·ÁÁ³½À´Ï´Ù [30]. ¶ÇÇÑ ¹Ì¼¼¾Æ±³¼¼Æ÷¿¡ ¹ßÇöÇÏ´Â PLC¥ã2 µ¿À§Ã¼ÀÇ ÀÛ¿ëÀÌ °­È­µÈ µ¹¿¬º¯ÀÌ¿¡ ÀÇÇØ ¹Ì¼¼¾Æ±³¼¼Æ÷ÀÇ ¸é¿ª È°¼ºÀÌ Áõ°¡ÇÔ°ú µ¿½Ã¿¡ ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ ÁøÇàÀÌ ´ÊÃçÁø´Ù´Â º¸°í°¡ ÀÕµû¸£°í ÀÖ½À´Ï´Ù [20,31]. ÇÑÆí ÇåÆÃÅϺ´ ȯÀÚ¿¡¼­ ÁøÇàµÈ À¯Àüü ¿¬±¸¿¡¼­, PLC¥â4 mRNA¹ßÇöÀÌ ¼¶À¯¾Æ¼¼Æ÷¿¡¼­ Áõ°¡ÇÑ °ÍÀÌ ¾Ë·ÁÁ³°í, ÀÌ ¶ÇÇÑ ÇåÆÃÅϺ´ÀÇ º´¸® ±âÀü ¿¬±¸ÀÇ ½Ç¸¶¸®°¡ µÉ °ÍÀÔ´Ï´Ù [7,25].

¿ì¿ïÁõÀº PLC¥â1°ú PLC¥ã1 ¸ðµÎ¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù. PLC¥â1ÀÇ °æ¿ì ½ºÆ®·¹½º¸¦ ÅëÇÑ ¿ì¿ïÇൿ À¯µµ µ¿¹° ¸ðµ¨¿¡¼­ mRNAÀÇ ¹ßÇöÀÌ °¨¼ÒÇÏ°í, Ç׿ì¿ïÁ¦¸¦ ó¸®ÇÏ¿´À» ¶§ ¹ßÇö·®ÀÌ È¸º¹µÇ´Â º¯È­°¡ È®ÀεǾú½À´Ï´Ù [7]. ÇÑÆí ¿ì¿ïÁõ¿¡¼­ ¹ß°ßµÇ´Â ³ú ¼¼Æ÷ÀÇ À§Ãà ¹× ¼¼Æ÷È°¼º °¨¼Ò°¡ BDNF-TrkB ½ÅÈ£Àü´Þ°æ·ÎÀÇ ¼èÅð¿Í °ü·ÃµÈ °ÍÀ¸·Î ¹àÇôÁö°í Àִµ¥, À̸¦ ¸Å°³ÇÏ´Â PLC¥ã1ÀÇ ¿ªÇÒ¿¡µµ °ü½ÉÀÌ ¸ð¾ÆÁý´Ï´Ù.

ÀÌ¿Ü¿¡µµ ¾ç±Ø¼º Àå¾Ö, Á¶Çöº´°ú °°ÀÌ ºñÁ¤»óÀûÀÎ ½Å°æÈ°¼º ±ÕÇüÀÌ ÀÛ¿ëÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁø Á¤¼­ÀÎÁöÁúȯ¿¡ À־µµ PLC¥â1 ¹× PLC¥ã1ÀÌ ¿¬°üµÆÀ» °ÍÀ̶ó´Â °¡¼³ÀÌ ²ÙÁØÈ÷ Á¦±âµË´Ï´Ù.

»ó¿°»öü ¿ì¼º ´ë³ú¹éÁúÀ§ÃàÁõ(ADLD, Autosomal dominant leukodystrophy)ÀÇ º´¸®Àû ±âÀü¿¡ ¶ó¹Î B1¿ÍÀÇ ¿¬°ü¼ºÀÌ ½Ã»çµÇ¾ú´Âµ¥, ÀÌ´Â ¶ó¹Î B1°ú »óÈ£ÀÛ¿ëÇÏ´Â PLC¥â1°ú ¿¬°üÀÌ ÀÖÀ» ¼ö ÀÖ½À´Ï´Ù. ¿îµ¿ ½ÇÁ¶ÁõÀº ¸Á¸·, ¼Ò³ú¿¡¼­ PLC¥â4ÀÇ ³ôÀº ¹ßÇö°ú °ü·ÃÀÌ ÀÖÀ¸¸ç, ÀÌ´Â PLC¥â4 ½ÅÈ£ Àü´ÞÀÇ ±â´É Àå¾Ö°¡ ¿îµ¿ ½ÇÁ¶Áõ ¹× ½Ã°¢ ó¸® °áÇÔ°ú °ü·ÃÀÌ ÀÖÀ» ¼ö ÀÖÀ½À» ½Ã»çÇÕ´Ï´Ù [7].

PLC¥ç´Â µ¿À§Ã¼ÀÇ Á¾·ù¿¡ µû¶ó ¼¼Æ÷ŸÀÔ ¼±ÅÃÀûÀ¸·Î Á¤¼­ÀÎÁö¸¦ ´ã´çÇÏ´Â ³ú¿µ¿ªµé¿¡ ¹ßÇöÇÏ°í ÀÖ´Â °ÍÀÌ ¾Ë·ÁÁ³À¸¸ç, ÇâÈÄ ³úÁúȯ°ú °ü·ÃµÈ ±× ±â´É¿¡ ´ëÇÑ ¿¬±¸°¡ ÇÊ¿äÇÕ´Ï´Ù.

[°á·Ð]

   Áö±Ý±îÁö ¸¹Àº ¿¬±¸ÀÚµéÀÇ ³ë·ÂÀ¸·Î PLCÀÇ ´Ù¾çÇÑ µ¿À§Ã¼ÀÇ ºÐ¼®°ú µ¿Á¤, ³ú ³» ºÐÆ÷, ½Ã³À½º ¹× ½Å°æ °¡¼Ò¼º¿¡¼­ÀÇ ¿ªÇÒ, ±×¸®°í Á¤¼­ÀÎÁöÀå¾Ö ¹× ½Å°æÀå¾Ö¿Í ¿¬°ü¼ºÀ» È®ÀÎÇÏ´Â µ¥ »ó´çÇÑ ÁøÀüÀ» ÀÌ·ç¾úÁö¸¸ PLCÀÇ ´ÙÃþÀûÀΠƯ¼º¿¡ ´ëÇÑ ¿ÏÀüÇÑ ÀÌÇØ´Â ¿©ÀüÈ÷ ¾î·Á¿î °úÁ¦ÀÔ´Ï´Ù. PLCÀÇ ½ºÇöóÀ̽º º¯ÀÌü¿¡ ´ëÇÑ ¿¬±¸¿¡ ´ëÇÑ °íÂûµµ ÇÊ¿äÇÒ °ÍÀÔ´Ï´Ù.

¶ÇÇÑ ¡°¿Ö ±×·¸°Ô ¸¹Àº PLC µ¿Á¾È¿¼Ò°¡ Á¸ÀçÇÏ´ÂÁö, ±×¸®°í ÀÌ·¯ÇÑ µ¿Á¾È¿¼Ò°¡ °¢ ¼¼Æ÷ ¶Ç´Â Á¶Á÷ À¯Çü¿¡¼­ ¾î¶»°Ô ÀûÀýÇÏ°Ô È°¿ë¡± µÇ´Â Áö¿¡ ´ëÇÑ Å½±¸°¡ À̾îÁ®¾ß ÇÒ °ÍÀÔ´Ï´Ù [5]. ¾Æ¸¶µµ, º¹ÀâÇÑ ³úÀÇ Á¤±³ÇÑ ÀÛµ¿ Á¶ÀýÀ» À§Çؼ­´Â ½Å°æÀü´Þ¹°Áú°ú ¼ö¿ëüµé °£ÀÇ ´Ù¾çÇÑ Á¶ÇÕ¿¡ ´õÇÏ¿© PLCµ¿À§Ã¼µé ÅëÇÑ ½ÅÈ£Àü´Þ °æ·ÎÀÇ ¸¹Àº °æ¿ìÀÇ ¼ö¸¦ ÅëÇÑ Á¤º¸Àü´Þ, ¼ÒÅë ü°è°¡ Á¸ÀçÇÏ°Ô µÈ °ÍÀ¸·Î »ý°¢µË´Ï´Ù. PLCÀÇ ´Ù¸éÀûÀÎ ¿ªÇÒ°ú »óÈ£ ¼ÒÅë¿¡ ´ëÇÑ ¿¬±¸´Â º¹ÀâÇÑ ³ú¿¡ ´ëÇÑ ºÐÀÚÀû ÀÌÇØÀÇ ÁøÀüÀÏ »Ó¸¸ ¾Æ´Ï¶ó Á¤¼­ ÀÎÁö Àå¾Ö¿¡ ´ëÇÑ ÀáÀçÀûÀÎ Ä¡·á¸¦ ÇâÇÑ ±æÀÏ °ÍÀÔ´Ï´Ù.

Âü°í¹®Çå

  • 1.

    Yoon BE, Lee CJ. (2014) GABA as a rising gliotransmitter. Front Neural Circuits. 8:141.

  • 2.

    Han KS, Woo J, Park H, Yoon BJ, Choi S, Lee CJ. (2013) Channel-mediated astrocytic glutamate release via Bestrophin-1 targets synaptic NMDARs. Mol Brain. 16;6:4.

  • 3.

    Lee JH, Kim JY, Noh S, Lee H, Lee SY, Mun JY, Park H, Chung WS. (2021) Astrocytes phagocytose adult hippocampal synapses for circuit homeostasis. Nature. 590(7847):612-617.

  • 4.

    Allen, N. J. (2014). Astrocyte regulation of synaptic behavior. Annual review of cell and developmental biology, 30, 439-463.

  • 5.

    Fukami, K., Inanobe, S., Kanemaru, K., & Nakamura, Y. (2010). Phospholipase C is a key enzyme regulating intracellular calcium and modulating the phosphoinositide balance. Progress in lipid research, 49(4), 429-437.

  • 6.

    Joensuu, M., Wallis, T., Saber, S. H., & Meunier, F. (2019). Phospholipases in neuronal function: A role in learning and memory? Journal of Neurochemistry

  • 7.

    Rusciano, I., Marvi, M. V., Obeng, E. O., Mongiorgi, S., Ramazzotti, G., Follo, M. Y., ... & Ratti, S. (2021). Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology. Advances in Biological Regulation, 79, 100771

  • 8.

    Suh, P.G., et al., Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep, (2008). 41(6): p. 415-34.

  • 9.

    Hwang JI, Oh YS, Shin KJ, Kim H, Ryu SH, Suh PG. (2005) Molecular cloning and characterization of a novel phospholipase C, PLC-eta. Biochem J. 389(Pt 1):181-6.

  • 10.

    Lim KH, Yang S, Kim SH, Ko E, Kang M, Joo JY. (2023) Cryptic mutations of PLC family members in brain disorders: recent discoveries and a deep-learning-based approach. Brain. 146(4):1267-1280.

  • 11.

    Nakahara M, Shimozawa M, Nakamura Y, Irino Y, Morita M, Kudo Y, Fukami K. (2005) A novel phospholipase C, PLC(eta)2, is a neuron-specific isozyme. J Biol Chem280(32):29128-34.

  • 12.

    Drissi, I., Fletcher, E., Shaheen, R., Nahorski, M., Alhashem, A., Lisgo, S., Fernandez-Jaen, A., Schon, K., Tlili-Graiess, K., Smithson, S., Lindsay, S., Sharpe, H. J., Alkuraya, F., & Woods, G. (2021). Mutations in phospholipase C eta-1 (PLCH1) are associated with holoprosencephaly. Journal of Medical Genetics.

  • 13.

    Kurian, M., Meyer, E., Vassallo, G., Morgan, N., Prakash, N., Pasha, S., Hai, N., Shuib, S., Rahman, F., Wassmer, E., Cross, J., O'callaghan, F., Osborne, J., Scheffer, I., Gissen, P., & Maher, E. (2010). Phospholipase C beta 1 deficiency is associated with early-onset epileptic encephalopathy. Brain.

  • 14.

    V.R. Lo Vasco, G. Cardinale, P. Polonia Deletion of PLCB1 gene in schizophrenia-affected patients J. Cell Mol. Med., 16 (2012), pp. 844-851,,.

  • 15.

    X.H. Lin, N. Kitamura, T. Hashimoto, O. Shirakawa, K. Maeda Opposite changes in phosphoinositide-specific phospholipase C immunoreactivity in the left prefrontal and superior temporal cortex of patients with chronic schizophrenia Biol. Psychiatr., 46 (1999), pp. 1665-1671.

  • 16.

    M. Orsetti, F. Brisco, M. Di Rinaldi, D. Dallorto, P. Ghi Some molecular effectors of antidepressant action of quetiapine revealed by DNA microarray in the frontal cortex of anhedonic rats Pharmacogenetics Genom., 19 (2009), pp. 600-612,.

  • 17.

    C.F. Kao, P. Jia, Z. Zhao, P.H. Kuo Enriched pathways for major depressive disorder identified from a genome-wide association study Int. J. Neuropsychopharmacol., 15 (2012), pp. 1401-1411,.

  • 18.

    Vaarmann, A., Gandhi, S., & Abramov, A. (2010). Dopamine Induces Ca2+ Signaling in Astrocytes through Reactive Oxygen Species Generated by Monoamine Oxidase. Journal of Biological Chemistry.

  • 19.

    Odaka, H., & Adachi, N. (2018). Actions of Brain-Derived Neurotrophin Factor in the Neurogenesis and Neuronal Function, and Its Involvement in the Pathophysiology of Brain Diseases. International Journal of Molecular Sciences.

  • 20.

    Magno, L., Lessard, C., Martins, M., Cruz, P., Katan, M., Bilsland, J., Chakrabaty, P., Golde, T., & Whiting, P. (2019). Alzheimer’s disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph. Alzheimer's Research & Therapy.

  • 21.

    H. Jiang, A. Lyubarsky, R. Dodd, N. Vardi, E. Pugh, D. Baylor, M.I. Simon, D. Wu Phospholipase C ¥â4 is involved in modulating the visual response in mice Proc. Natl. Acad. Sci. U.S.A., 93 (1996), pp. 14598-14601, 10.1073/pnas.93.25.14598.

  • 22.

    Hong, J., Lee, J., Song, K., Ha, G. E., Yang, Y. R., Ma, J. S., ... & Cheong, E. (2016). The thalamic mGluR1-PLC¥â4 pathway is critical in sleep architecture. Molecular brain, 9, 1-12.

  • 23.

    A.B.M. Cunha, B.N. Frey, A.C. Andreazza, J.D. Goi, A.R. Rosa, C.A. Goncalves, A. Santin, F. Kapczinski (2006) Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes Neurosci. Lett., 398, pp. 215-219, 10.1016/j.neulet.2005.12.085.

  • 24.

    Kim, H. Y., Yang, Y. R., Hwang, H., Lee, H. E., Jang, H. J., Kim, J., ... & Kim, J. I. (2019). Deletion of PLC¥ã1 in GABAergic neurons increases seizure susceptibility in aged mice. Scientific reports, 9(1), 17761.

  • 25.

    A. Giralt, T. Rodrigo, E.D. Martin, J.R. Gonzalez, M. Mila, V. Cena, M. Dierssen, J.M. Canals, J. Alberch (2009) Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseC¥ã activity and glutamate receptor expression Neuroscience, 158, pp. 1234-1250, 10.1016/j.neuroscience.2008.11.024.

  • 26.

    T. Hashimoto, S.E. Bergen, Q.L. Nguyen, B. Xu, L.M. Monteggia, J.N. Pierri, Z. Sun, A.R. Sampson, D.A. Lewis (2005) Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia J. Neurosci., 25, pp. 372-383,.

  • 27.

    Andreone, B. J., Przybyla, L., Llapashtica, C., Rana, A., Davis, S. S., van Lengerich, B., ... & Lewcock, J. W. (2020). Alzheimer’s-associated PLC¥ã2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia. Nature Neuroscience, 23(8), 927-938.

  • 28.

    Dusaban S.S., Purcell N.H., Rockenstein E., Masliah E., Cho M.K., Smrcka A.V., Brown J.H. (2013) Phospholipase C epsilon links G protein-coupled receptor activation to inflammatory astrocytic responses. Proc. Natl. Acad. Sci. U. S. A. 110, 3609-3614.

  • 29.

    Chang B, Byun J, Kim KK, Lee SE, Lee B, Kim KS, Ryu H, Shin HS, Cheong E. (2022) Deletion of Phospholipase C ¥â1 in the Thalamic Reticular Nucleus Induces Absence Seizures. Exp Neurobiol. 31(2):116-130.

  • 30.

    Hayashi H, Campenot RB, Vance DE, Vance JE. (2009) Protection of neurons from apoptosis by apolipoprotein E-containing lipoproteins does not require lipoprotein uptake and involves activation of phospholipase Cgamma1 and inhibition of calcineurin. J Biol Chem. 284(43):29605-13.

  • 31.

    Li K, Ran B, Wang Y, Liu L, Li W. (2022) PLC¥ã2 impacts microglia-related effectors revealing variants and pathways important in Alzheimer's disease. Front Cell Dev Biol.10:999061.